Kazia Therapeutics (KZIA) Accounts Payables (2009 - 2025)

Kazia Therapeutics (KZIA) has 14 years of Accounts Payables data on file, last reported at $6.3 million in Q4 2025.

• In Q4 2025, Accounts Payables fell 7.39% year-over-year to $6.3 million; the TTM figure through Dec 2025 stood at $6.3 million (down 7.39% YoY), while the FY2025 annual figure was $6.5 million, down 34.75% from the prior year.
• Accounts Payables declined to $6.3 million in Q4 2025, from $6.5 million in the prior quarter.
• Across five years, Accounts Payables topped out at $9.9 million in Q2 2024 and bottomed at $2.1 million in Q4 2022.
• A 5-year average of $5.0 million and a median of $3.9 million in 2023 frame the typical range for Accounts Payables.
• Annual changes were most pronounced in 2024 — Accounts Payables surged 243.19% — and 2025, when it sank 34.75%.
• Year by year, Accounts Payables stood at $3.8 million in 2021, then sank by 45.54% to $2.1 million in 2022, then surged by 88.38% to $3.9 million in 2023, then jumped by 75.51% to $6.8 million in 2024, then slipped by 7.39% to $6.3 million in 2025.
• The last three Accounts Payables figures came in at $6.3 million (Q4 2025), $6.5 million (Q2 2025), and $6.8 million (Q4 2024), per Business Quant data.

Peer Comparison